Alex Zhavoronkov

Alex Zhavoronkov is the current Founder and CEO at Insilico Medicine, a previous company they had also been a part of. Alex has also been an International Adjunct Professor at Moscow Institute of Physics and Technology (State University) from November 2013 to January 2015. Zhavoronkov has also been a Consultant for Sequenom from March 2009 to December 2011 and an Advisor for Biogerontology Research Foundation from February 2008 to December 2018. Head of the Regenerative Medicine Laboratory at Center for Pediatric Hematology, Oncology and Immunology from October 2011 to January 2014.

Alex Zhavoronkov has a Bachelor of Commerce (Honors) from Queen's University in Finance, Management of Information Systems. Alex also has a PhD in Physics from Lomonosov Moscow State University (MSU). Additionally, they have a Master of Science in Biotechnology from The Johns Hopkins University and a Bachelor of Science in Computer Science from Queen's University. Alex also has certificates from the Canadian Securities Institute in CSC, CPH courses and from NCBI in the Power Scripting Course.

Some individuals on their team include Min Fang - Managing Director of Healthcare, Feng Ren - Chief Scientific Officer, and Kan Chen - Principal of Qiming Venture Partners.